Add a listing
    Add a listing

    Cytegen

      Developer of proprietary discovery platform designed to increase healthspan by reversing the age-related disease

    General
    • Headquarters

      Wauwatosa, Wisconsin, United States

    • Founders & Team

      Nuray George Ugras

    • Year Founded

      2015

    • Company type

      Private company

    • Funding stage

      Seed

    • Total funding ($M)

      1

    • Investors

      Peter Thiel

    Technical Details
    • Aging Target

      Mitochondrial dysfunction

    • Product modality

      proteins, small molecule drugs

    • Clinical stage

      Pre-clinical

    About

    CyteGen’s hypothesis is that exercise induces the secretion of blood-borne proteins that act systemically to stimulate removal of damaged mitochondria and enrichment of healthy mitochondria mitochondrial fitness,” the application says. “The company’s goal is to identify these proteins to develop into biologics that would serve as a platform to treat the myriad of diseases associated with mitochondrial dysfunction.

    Categories

    How much is an extra decade of life worth to you? Make a bet on longevity science today.

    Donate to Impetus Grants

    You May Also Be Interested In